474 related articles for article (PubMed ID: 19620873)
1. Aspirin is not chemoprotective for Barrett's adenocarcinoma of the oesophagus in multicentre cohort.
Gatenby PA; Ramus JR; Caygill CP; Winslet MC; Watson A
Eur J Cancer Prev; 2009 Sep; 18(5):381-4. PubMed ID: 19620873
[TBL] [Abstract][Full Text] [Related]
2. Chemoprevention in Barrett's oesophagus.
Gordon V; Jankowski J
Best Pract Res Clin Gastroenterol; 2011 Aug; 25(4-5):569-79. PubMed ID: 22122772
[TBL] [Abstract][Full Text] [Related]
3. A surveillance programme for Barrett's oesophagus in a UK general hospital.
Olithselvan A; Gorard DA; McIntyre AS
Eur J Gastroenterol Hepatol; 2007 Apr; 19(4):305-9. PubMed ID: 17353694
[TBL] [Abstract][Full Text] [Related]
4. Daily use of non-steroidal anti-inflammatory drugs is less frequent in patients with Barrett's oesophagus who develop an oesophageal adenocarcinoma.
Tsibouris P; Hendrickse MT; Isaacs PE
Aliment Pharmacol Ther; 2004 Sep; 20(6):645-55. PubMed ID: 15352913
[TBL] [Abstract][Full Text] [Related]
5. Surveillance in Barrett's oesophagus: will a strategy focused on a high-risk group reduce mortality from oesophageal adenocarcinoma?
Quera R; O'Sullivan K; Quigley EM
Endoscopy; 2006 Feb; 38(2):162-9. PubMed ID: 16479424
[TBL] [Abstract][Full Text] [Related]
6. Dysplasia and risk of further neoplastic progression in a regional Veterans Administration Barrett's cohort.
Dulai GS; Shekelle PG; Jensen DM; Spiegel BM; Chen J; Oh D; Kahn KL
Am J Gastroenterol; 2005 Apr; 100(4):775-83. PubMed ID: 15784018
[TBL] [Abstract][Full Text] [Related]
7. Nonsteroidal anti-inflammatory drugs and statins have chemopreventative effects in patients with Barrett's esophagus.
Kastelein F; Spaander MC; Biermann K; Steyerberg EW; Kuipers EJ; Bruno MJ;
Gastroenterology; 2011 Dec; 141(6):2000-8; quiz e13-4. PubMed ID: 21878200
[TBL] [Abstract][Full Text] [Related]
8. Effect of proton pump inhibitors on markers of risk for high-grade dysplasia and oesophageal cancer in Barrett's oesophagus.
Hillman LC; Chiragakis L; Shadbolt B; Kaye GL; Clarke AC
Aliment Pharmacol Ther; 2008 Feb; 27(4):321-6. PubMed ID: 18047565
[TBL] [Abstract][Full Text] [Related]
9. Dysplasia and cancer in a large multicenter cohort of patients with Barrett's esophagus.
Sharma P; Falk GW; Weston AP; Reker D; Johnston M; Sampliner RE
Clin Gastroenterol Hepatol; 2006 May; 4(5):566-72. PubMed ID: 16630761
[TBL] [Abstract][Full Text] [Related]
10. The incidence of adenocarcinoma and dysplasia in Barrett's esophagus: report on the Cleveland Clinic Barrett's Esophagus Registry.
O'Connor JB; Falk GW; Richter JE
Am J Gastroenterol; 1999 Aug; 94(8):2037-42. PubMed ID: 10445525
[TBL] [Abstract][Full Text] [Related]
11. Barrett's oesophagus: the new endoscopic modalities have a future.
Deviere J
Gut; 2005 Mar; 54 Suppl 1(Suppl 1):i33-7. PubMed ID: 15711006
[TBL] [Abstract][Full Text] [Related]
12. Long-term endoscopic surveillance of patients with Barrett's esophagus. Incidence of dysplasia and adenocarcinoma: a prospective study.
Conio M; Blanchi S; Lapertosa G; Ferraris R; Sablich R; Marchi S; D'Onofrio V; Lacchin T; Iaquinto G; Missale G; Ravelli P; Cestari R; Benedetti G; Macrì G; Fiocca R; Munizzi F; Filiberti R
Am J Gastroenterol; 2003 Sep; 98(9):1931-9. PubMed ID: 14499768
[TBL] [Abstract][Full Text] [Related]
13. Cancer risk in Barrett's oesophagus.
Dias Pereira A; Suspiro A; Chaves P
Eur J Gastroenterol Hepatol; 2007 Nov; 19(11):915-8. PubMed ID: 18049157
[TBL] [Abstract][Full Text] [Related]
14. Review article: Barrett's oesophagus and carcinoma in Japan.
Hongo M
Aliment Pharmacol Ther; 2004 Dec; 20 Suppl 8():50-4. PubMed ID: 15575874
[TBL] [Abstract][Full Text] [Related]
15. Barrett's esophagus: a retrospective analysis of 13 years surveillance.
Switzer-Taylor V; Schlup M; Lübcke R; Livingstone V; Schultz M
J Gastroenterol Hepatol; 2008 Sep; 23(9):1362-7. PubMed ID: 18205769
[TBL] [Abstract][Full Text] [Related]
16. Incidence of adenocarcinoma among patients with Barrett's esophagus.
Hvid-Jensen F; Pedersen L; Drewes AM; Sørensen HT; Funch-Jensen P
N Engl J Med; 2011 Oct; 365(15):1375-83. PubMed ID: 21995385
[TBL] [Abstract][Full Text] [Related]
17. Low-grade dysplasia in Barrett's esophagus has a high risk of progression.
Lim CH; Treanor D; Dixon MF; Axon AT
Endoscopy; 2007 Jul; 39(7):581-7. PubMed ID: 17611911
[TBL] [Abstract][Full Text] [Related]
18. Systematic four-quadrant biopsy detects Barrett's dysplasia in more patients than nonsystematic biopsy.
Abela JE; Going JJ; Mackenzie JF; McKernan M; O'Mahoney S; Stuart RC
Am J Gastroenterol; 2008 Apr; 103(4):850-5. PubMed ID: 18371135
[TBL] [Abstract][Full Text] [Related]
19. High-grade dysplasia in Barrett's oesophagus: natural history and review of clinical practice.
Thomas T; Richards CJ; de Caestecker JS; Robinson RJ
Aliment Pharmacol Ther; 2005 Mar; 21(6):747-55. PubMed ID: 15771761
[TBL] [Abstract][Full Text] [Related]
20. Does a surgical antireflux procedure decrease the incidence of esophageal adenocarcinoma in Barrett's esophagus? A meta-analysis.
Corey KE; Schmitz SM; Shaheen NJ
Am J Gastroenterol; 2003 Nov; 98(11):2390-4. PubMed ID: 14638338
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]